KPV vs BPC-157: structure, research and status

KPV and BPC-157 are both short synthetic peptides discussed in inflammation and tissue-repair research, but they are very different molecules. KPV is a three-residue fragment (Lys-Pro-Val) of the hormone alpha-MSH, studied mainly in mouse colitis and skin-inflammation models. BPC-157 is a 15-residue peptide based on a protein found in human gastric juice, studied mainly in rat injury and healing models. Neither is an approved medicine, human data for both are thin, and in October 2026 both were among the six peptides named in a new US enforcement-discretion policy for pharmacy compounding. This page compares their structure, the research behind each, and their regulatory position.

Structure and molecular data side by side

The two peptides share no sequence and come from unrelated parent proteins. That matters at the bench: different weights and different analytical checks.

What KPV research covers

Alpha-MSH is a neuropeptide with anti-inflammatory activity, but it also drives pigmentation. KPV, its last three residues, was investigated as a smaller fragment that might keep some of the anti-inflammatory effect. The key published work includes:

• Mouse colitis (2008). Kannengiesser and colleagues at the University of Münster tested KPV in dextran sulfate sodium (DSS) colitis and in CD45RBhi T-cell transfer colitis. Treated mice recovered weight earlier and showed fewer inflammatory infiltrates and lower colonic myeloperoxidase activity. In mice lacking a functional melanocortin-1 receptor (MC1R), KPV still worked, so the authors concluded its effect is at least partly independent of MC1R.
• Intestinal uptake (2008). A Gastroenterology paper by Dalmasso and colleagues reported that KPV is taken up by the intestinal peptide transporter PepT1 and that this uptake reduced intestinal inflammation in their models.
• Brain injury (2013). Schaible and colleagues gave alpha-MSH(11–13) once after controlled cortical impact in mice and reported smaller secondary lesion volume, less microglial activation and less neuronal apoptosis. Notably, classic inflammatory markers TNF-alpha and IL-1 beta were not reduced.
• Reviews. A 2023 review in Cells on the melanocortin system in inflammatory bowel disease lists KPV among candidate molecules, with evidence drawn from mouse models.

FDA's compounding safety page states that the agency "has not identified any human exposure data on drug products containing KPV administered via any route of administration."

What BPC-157 research covers

BPC-157 was described by Predrag Sikiric's group in Zagreb in 1993. Most of its literature comes from rodent studies of gut lesions, tendons and ligaments, including rat Achilles tendon and ligament repair work. Reported themes are cytoprotection, effects on blood-vessel growth and tissue healing. Pharmacokinetic work in rats measured an elimination half-life of roughly 7.9 to 30 minutes. Reviewers have raised the concern that a compound promoting angiogenesis could, in principle, feed tumor growth.

Human evidence is scarce. A July 2026 Pharmacy Times review counted three uncontrolled pilot studies with about 30 participants combined, and noted no validated human pharmacokinetic data, no identified receptor and no long-term human safety data. For how BPC-157 compares with its usual pairing, see BPC-157 vs TB-500.

Evidence quality compared

Neither peptide has clinical-grade evidence. KPV has a tidier mechanistic story; BPC-157 has a far larger animal literature.

Regulatory status in October 2026

In 2023 FDA placed BPC-157 and more than a dozen other peptides in Category 2 of its interim bulk-substance policy (substances raising significant safety concerns). On 15 April 2026 FDA said it would remove 12 peptides from Category 2 and refer them to its Pharmacy Compounding Advisory Committee. On 23–24 July 2026 that committee voted 8–6, with one abstention, to recommend both BPC-157 and KPV for the 503A bulks list. The votes are advisory, and FDA has not begun rulemaking. More on that meeting is in our FDA peptide vote explainer.

On 28 October 2026 HHS announced an enforcement-discretion policy covering six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. It says HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding these under section 503A. It is temporary, non-binding, does not add anything to the bulks list and does not approve any product. It also does not turn research-use-only powder into a medicine. Details are in our HHS compounding policy guide; for the wider legal picture see are peptides legal? and, for Britain, research peptides in the UK.

In sport, WADA has prohibited BPC-157 since 1 January 2022 under section S0 (non-approved substances).

Lab bench notes

For in-vitro work, the size difference changes the arithmetic. A 1 mM stock of KPV needs about 0.342 mg per mL of solvent; the same molarity of BPC-157 needs about 1.42 mg per mL. Those figures use free-peptide molar masses. Supplied material is often a salt (for example trifluoroacetate) with a higher formula weight, so use the weight stated on the batch certificate. Our peptide calculator handles the molarity math, and how to verify a peptide CoA explains what identity and purity data to expect.

Frequently asked questions

Sources

1. Wikipedia: BPC-157 (sequence, formula, molar mass, research summary, WADA status; accessed October 2026)
2. Wikipedia: KPV tripeptide (formula, molar mass, cited studies; accessed October 2026)
3. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD. Inflamm Bowel Dis (2008)
4. Schaible EV et al. Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage after experimental TBI in mice. PLoS ONE (2013)
5. Gravina AG et al. The melanocortin system in inflammatory bowel diseases. Cells (2023), PMID 37508552
6. Pharmacy Times: Heal or harm? Body Protective Compound 157 in the gray zone (1 July 2026)
7. FDA: Safety risks associated with certain bulk drug substances nominated for use in compounding (updated 22 April 2026)
8. Holland & Knight: Peptides at a crossroads (16 October 2026)
9. Lachman Consultants: HHS breaks with FDA scientists on 503A peptide compounding (28 October 2026)
10. Federal Register (public inspection): Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (October 2026)
11. STAT: HHS enforcement discretion policy allows peptide compounding (28 October 2026)